You are here: Industry Insights > Shionogi

News List

Shionogi’s novel antibiotic added to UK’s pilot subscription reimbursement model pharmatimes
December 24, 2020
Shionogi’s novel antibiotic Fetcroja (cefiderocol) has been selected by the UK’s National Institute for Health and Care Excellence (NICE) and the National Health Service England and Improvement (NHSE&I) to be included in a pilot subscription ...
Shionogi launches novel antibiotic Fetcroja in the UK pharmatimes
September 16, 2020
Japanese pharma company Shionogi has announced that its new antibiotic Fetcroja (cefiderocol) is now available for use in the UK, the first country to launch the drug following its European Commission (EC) approval earlier this year.
FDA Accepts sNDA with Priority Review for FETROJA americanpharmaceuticalreview
June 11, 2020
Shionogi announced the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for FETROJA® (cefiderocol) and granted Priority Review designation ...
Shionogi to buy Tetra Therapeutics in $500m deal pharmaceutical-business-review
May 28, 2020
Shionogi has agreed to acquire clinical-stage biotechnology company Tetra Therapeutics in a deal valued at around $500m.
Shionogi works on Covid-19 therapies and vaccine pharmaceutical-technology
April 30, 2020
Japanese-based Shionogi has partnered with public institutions, academia and other companies to develop potential drugs and vaccine against Covid-19.
Shionogi’s thrombocytopenia drug secures approval for use on NHS pharmaceutical-technology
December 16, 2019
Japanese company Shionogi has received approval for Mulpleo (lusutrombopag) drug on the National Health Service (NHS) in England ...
Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag americanpharmaceuticalreview
June 26, 2019
Shionogi announces the Company has concluded an agreement with Eddingpharm to license-out lusutrombopag, a thrombopoietin receptor agonist (brand name in Japan: MULPLETA®).
Shionogi agrees to license-out lusutrombopag pharmaceutical-technology
June 26, 2019
Shionogi & Co has concluded an agreement with China’s Eddingpharm to license-out its thrombopoietin receptor agonist lusutrombopag.
Sandoz to commercialise Shionogi’s Rizmoic in European markets pharmaceutical-technology
April 23, 2019
Sandoz to commercialise Shionogi’s Rizmoic in European markets...
Acquisition of Marketing Approval for VYVANSE Capsule 20mg/30mg for …… firstwordpharma
April 15, 2019
VYVANSE® is a once-daily drug that stimulates the release and blocks the reuptake of dopaminenoradrenaline.

Previous page 1 2 Next page